[PRNewswire] Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for Praluent™ (alirocumab). Alirocumab is an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9) that is intended for the treatment of patients with hypercholesterolemia.
The MAA for Praluent contains data from more than 5,000 patients, including 10 Phase 3 ODYSSEY trials. Together with additional ongoing studies including ODYSSEY OUTCOMES, the ODYSSEY clinical trial program will include more than 23,500 patients at more than 2,000 study centers in double-blind, randomized, placebo-and active-controlled trials ranging from 24 weeks to approximately 5 years. To view the full article click here.
Regeneron Pharmaceuticals Inc (REGN), On 11/4/2014, REGN reported 3 quarter 2014 earnings of $2.52 per share. This result was in-line with the consensus of the 15 analysts following the company and beat last year’s 3 quarter results by $1.27. The next confirmed earnings announcement is expected on 02/10/2015.
Insufficient price earnings data. REGN’s PE ratio is among the highest of any stock in the Biotechnology & Drugs industry and signals that investors have high hopes for this company’s future business prospects.
Regeneron Pharmaceuticals Inc (REGN)‘s PE ratio is among the lowest of any stock in the Semiconductors industry and signals that investors have not been willing to pay a premium for this company’s business prospects. Additionally, during the past year, earnings growth has outpaced its historical five year growth rate.
In terms of ratings, there are seventeen analysts that cover the stock which have provided Q4 2014 earnings per share estimates. The consensus anticipated number for the upcoming quarter is $2.75. The highest estimate is $3.16 while the lowest is $1.96. The company has a one year EPS growth rate of -43.55%.
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. Regeneron develops new product candidate using VelociSuite technology platforms. Regeneron’s discovery platforms are designed to identify specific proteins of therapeutic interest for a particular disease or cell type and validate these targets through high-throughput production of genetically modified mice using the Company’s VelociGene technology to understand the role of these proteins in normal physiology, as well as in models of disease. The Company also has human monoclonal antibody technology, VelocImmune and cell line expression technology VelociMab. Regeneron’s antibody product candidates in clinical trials were developed using VelocImmune. The Company has three marketed products: EYLEA, ZALTRAP and ARCALYST.